MILPITAS, Calif., Oct. 13, 2016 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that the company
will present two posters detailing clinical data from a Phase 1
clinical trial of PTG-100 and preclinical
pharmacokinetics/pharmacodynamics data on that compound at United
European Gastroenterology (UEG) Week. PTG-100 is a potential
first-in-class, oral alpha-4-beta-7 integrin-specific antagonist
peptide product candidate that Protagonist is developing initially
for the treatment of moderate-to-severe ulcerative colitis.
The global gastroenterology congress will be held in
Vienna, Austria from October 15 - 19, 2016.
Poster Presentations:
Poster Number
P0298: Safety, Pharmacokinetics and Pharmacodynamics of
the Novel Oral Peptide Therapeutic PTG-100 (alpha4-beta7 Integrin
Antagonist) in Normal Healthy Volunteers
|
Date and
time:
|
Monday October 17,
10:30 - 17:00, presentation 12:30 - 13:30 CET
|
Place:
|
Poster Exhibition --
Hall X4 and X5
|
Poster
Session:
|
IBD I
|
Presenting
author:
|
Richard S. Shames,
MD, Protagonist Chief Medical Officer
|
|
|
Poster Number
P0792: Pharmacokinetics and Pharmacodynamics Following Oral
Administration of PTG-100, a Peptide Antagonist of Integrin
alpha4-beta7
|
Date and time:
|
Tuesday October 18,
9:00 to 17:00, presentation 12:30 - 13:30 CET
|
Place:
|
Poster Exhibition --
Hall X4 and X5
|
Poster
Session:
|
IBD II
|
Presenting author:
|
Thamilarasi
Annamalai, M.S., Protagonist Senior Director, Preclinical
Development
|
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical
company with a proprietary technology platform focused on
discovering and developing peptide-based new chemical entities to
address significant unmet medical needs. Its primary focus is on
developing first-in-class oral peptide drugs that specifically
target biological pathways also targeted by currently marketed
injectable antibody drugs. Compared to injectable antibody drugs,
Protagonist's oral peptides offer targeted delivery to the
gastrointestinal (GI) tissue compartment, potential for improved
safety due to minimal exposure in the blood, improved convenience
and compliance due to oral delivery, and potentially an opportunity
for earlier introduction of targeted therapy for inflammatory bowel
disease (IBD). Protagonist's initial lead product candidates,
PTG-100 and PTG-200, are based on this approach, and the company
believes they have the potential to transform the existing
treatment paradigm for IBD, a GI disease consisting primarily of
ulcerative colitis and Crohn's disease.
PTG-100, a potential first-in-class oral alpha-4-beta-7 integrin
specific antagonist peptide product candidate that is being
developed initially for moderate-to-severe ulcerative colitis, has
now completed a phase 1 clinical trial in normal healthy
volunteers. PTG-200, a potential first-in-class oral
Interleukin-23 receptor antagonist that is being developed
initially for moderate-to-severe Crohn's disease, is currently in
IND-enabling studies.
The company has a peptide technology platform that enables the
discovery of oral and injectable peptides that can be utilized
against a diverse set of targets and diseases including, but not
confined to, GI targets and diseases. In addition to PTG-100 and
PTG-200, the company is engaged in the discovery and development of
injectable hepcidin mimetics, including one lead compound from this
program, PTG-300, which is currently in pre-clinical development.
These mimetics have potential utility for the treatment of iron
overload disorders, such as transfusion dependent beta-thalassemia,
hereditary hemochromatosis (HH) and sickle cell disease (SCD), each
of which may qualify PTG-300 for orphan drug
designation.
Protagonist is headquartered in Milpitas, California with its pre-clinical and
clinical staff in California, and
discovery operations both in California and in Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
Logo
- http://photos.prnewswire.com/prnh/20130501/MM06086LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-phase-1-clinical-and-preclinical-data-on-ptg-100-at-ueg-week-vienna-300344780.html
SOURCE Protagonist Therapeutics, Inc.